PCI – 7th June 2024
Temax_Krautz
Owen Mumford 12 January 2022, 17:40

Current Edition

Nasal & Pulmonary Drug Development
Cormica Banner Ad – 24.02.2025
Novo Nordisk 20 March 2024, 11:21
Biosynth: Fri 4 October 2024, 10:42

Almac Appoints Global Energy Manager as part of  ongoing commitment to net zero strategy  

The Almac Group has announced the appointment of Ramees Raja as Global Energy Manager.

This is a new role that will drive actions to support Almac’s commitment to be net zero by 2045 and to reduce the Group’s Scope One and Scope two emissions by 50 percent, by 2030. 

Ramees will work closely with Almac Group’s Corporate Social Responsibility and Procurement teams to develop business improvement initiatives across the globe. These initiatives will include the use of solar panels across various Almac buildings, participation in power purchase agreements, moving away from the use of natural gas and the continued roll-out of our energy management standard ISO5001 across all operational Almac sites.

Ramees has more than 12 years of experience working with a range of organisations, including Ameeri Industries and Iqonomic.  He joined Almac from Muntons where he was Group Energy Manager, responsible for the group’s Energy Management and Renewable Energy Projects.

Ramees holds a BEng in Electrical and Electronic Engineering and MSc in Renewable Energy Engineering.

Niall Harkin, Almac Group Executive Director said: “It gives me great pleasure to announce Ramees’ appointment as Global Energy Manager. His wealth of expertise and experience will be instrumental in progressing our sustainability commitments.”

ENDS

About Almac Group  The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and 

commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture. 

The international company is a privately owned organisation that has grown organically over the past five decades now employing over 6,500 highly skilled personnel across 18 facilities including Europe, the USA and Asia. 

Stoelzle Skyscraper: 27th November 2024
Chemspec Europe – 27.02.2025
PHARMAP: Mon 14 October 2024, 10.36
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
LBBOHLE, Thu 20 April 2023, 17:23
Nipro 14 March 2024, 11:35